|
1
|
Qi J, Li M, Wang L, Hu Y, Liu W, Long Z,
Zhou Z, Yin P and Zhou M: National and subnational trends in cancer
burden in China, 2005-20: An analysis of national mortality
surveillance data. Lancet Public Health. 8:e943–e955. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin L, Li Z, Yan L, Liu Y, Yang H and Li
H: Global, regional, and national cancer incidence and death for 29
cancer groups in 2019 and trends analysis of the global cancer
burden, 1990–2019. J Hematol Oncol. 14:1972021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zaimy MA, Saffarzadeh N, Mohammadi A,
Pourghadamyari H, Izadi P, Sarli A, Moghaddam LK, Paschepari SR,
Azizi H, Torkamandi S and Tavakkoly-Bazzaz J: New methods in the
diagnosis of cancer and gene therapy of cancer based on
nanoparticles. Cancer Gene Ther. 24:233–243. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cao J, Huang D and Peppas NA: Advanced
engineered nanoparticulate platforms to address key biological
barriers for delivering chemotherapeutic agents to target sites.
Adv Drug Deliv Rev. 167:170–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Williams HD, Trevaskis NL, Charman SA,
Shanker RM, Charman WN, Pouton CW and Porter CJ: Strategies to
address low drug solubility in discovery and development. Pharmacol
Rev. 65:315–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang L, Jiang W, Wu L, Yu X, He Z, Shan W,
Fu L, Zhang Z and Zhao Y: TPGS2000-DOX prodrug micelles for
improving breast cancer therapy. Int J Nanomedicine. 16:7875–7890.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu Y, Wang Z, Han L, Guo Z, Yan B, Guo L,
Zhao H, Wei M, Hou N, Ye J, et al: PRMT5 regulates RNA m6A
demethylation for doxorubicin sensitivity in breast cancer. Mol
Ther. 30:2603–2617. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Etrych T, Daumová L, Pokorná E, Tušková D,
Lidický O, Kolářová V, Pankrác J, Šefc L, Chytil P and Klener P:
Effective doxorubicin-based nano-therapeutics for simultaneous
malignant lymphoma treatment and lymphoma growth imaging. J Control
Release. 289:44–55. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan D, Wei H, Lai X, Ge Y, Xu S, Meng J,
Wen T, Liu J, Zhang W, Wang J and Xu H: Co-delivery of
homoharringtonine and doxorubicin boosts therapeutic efficacy of
refractory acute myeloid leukemia. J Control Release. 327:766–778.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Almajidi YQ, Kadhim MM, Alsaikhan F, Turki
Jalil A, Hassan Sayyid N, Alexis Ramírez-Coronel A, Hassan Jawhar
Z, Gupta J, Nabavi N, Yu W and Ertas YN: Doxorubicin-loaded
micelles in tumor cell-specific chemotherapy. Environ Res.
227:1157222023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hong Y, Che S, Hui B, Yang Y, Wang X,
Zhang X, Qiang Y and Ma H: Lung cancer therapy using doxorubicin
and curcumin combination: Targeted prodrug based, pH sensitive
nanomedicine. Biomed Pharmacother. 112:1086142019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu L and Lin M: The synthesis of
nano-doxorubicin and its anticancer effect. Anticancer Agents Med
Chem. 21:2466–2477. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fernandez-Fernandez A, Manchanda R and
McGoron AJ: Theranostic applications of nanomaterials in cancer:
Drug delivery, image-guided therapy, and multifunctional platforms.
Appl Biochem Biotechnol. 165:1628–1651. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Yin X, Li C, Yin X, Xue Q, Ding
L, Ju J, Ma J, Zhu Y, Du D, et al: A Multifunctional
Photoacoustic/Fluorescence Dual-Mode-Imaging Gold-Based Theranostic
Nanoformulation without External Laser Limitations. Adv Mater.
34:e21106902022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Patel SC, Lee S, Lalwani G, Suhrland C,
Chowdhury SM and Sitharaman B: Graphene-based platforms for cancer
therapeutics. Ther Deliv. 7:101–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin J, Chen X and Huang P: Graphene-based
nanomaterials for bioimaging. Adv Drug Deliv Rev. 105((Pt B)):
242–254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao H, Ding R, Zhao X, Li Y, Qu L, Pei H,
Yildirimer L, Wu Z and Zhang W: Graphene-based nanomaterials for
drug and/or gene delivery, bioimaging, and tissue engineering. Drug
Discov Today. 22:1302–1317. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Díez-Pascual AM: Carbon-Based
Nanomaterials. Int J Mol Sci. 22:77262021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oh B and Lee CH: Development of
thiolated-graphene quantum dots for regulation of ROS in
macrophages. Pharm Res. 33:2736–2747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Chen L, Shen B, Chen L, Mo J and
Feng J: Dual-Sensitive graphene oxide loaded with proapoptotic
peptides and anticancer drugs for cancer synergetic therapy.
Langmuir. 35:6120–6128. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharifi S, Behzadi S, Laurent S, Forrest
ML, Stroeve P and Mahmoudi M: Toxicity of nanomaterials. Chem Soc
Rev. 41:2323–2343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guan M, Li J, Jia Q, Ge J, Chen D, Zhou Y,
Wang P, Zou T, Zhen M, Wang C and Shu C: A versatile and clearable
nanocarbon theranostic based on carbon dots and gadolinium
metallofullerene nanocrystals. Adv Healthc Mater. 5:2283–2294.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peer D, Karp JM, Hong S, Farokhzad OC,
Margalit R and Langer R: Nanocarriers as an emerging platform for
cancer therapy. Nat Nanotechnol. 2:751–760. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan Y, Cai T, Xia X, Zhang R, Chiba P and
Cai Y: Nanoparticle delivery of anticancer drugs overcomes
multidrug resistance in breast cancer. Drug Deliv. 23:3350–3357.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Donahue ND, Acar H and Wilhelm S: Concepts
of nanoparticle cellular uptake, intracellular trafficking, and
kinetics in nanomedicine. Adv Drug Deliv Rev. 143:68–96. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li R, Wang Y, Du J, Wang X, Duan A, Gao R,
Liu J and Li B: Graphene oxide loaded with tumor-targeted peptide
and anti-cancer drugs for cancer target therapy. Sci Rep.
11:17252021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cagel M, Grotz E, Bernabeu E, Moretton MA
and Chiappetta DA: Doxorubicin: Nanotechnological overviews from
bench to bedside. Drug Discov Today. 22:270–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thorn CF, Oshiro C, Marsh S,
Hernandez-Boussard T, McLeod H, Klein TE and Altman RB: Doxorubicin
pathways: Pharmacodynamics and adverse effects. Pharmacogenet
Genomics. 21:440–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen K, Cai H, Zhang H, Zhu H, Gu Z, Gong
Q and Luo K: Stimuli-responsive polymer-doxorubicin conjugate:
Antitumor mechanism and potential as nano-prodrug. Acta Biomater.
84:339–355. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dharmaraja AT: Role of reactive oxygen
species (ROS) in therapeutics and drug resistance in cancer and
bacteria. J Med Chem. 60:3221–3240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheung EC and Vousden KH: The role of ROS
in tumour development and progression. Nat Rev Cancer. 22:280–297.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sp N, Kang DY, Jo ES, Rugamba A, Kim WS,
Park YM, Hwang DY, Yoo JS, Liu Q, Jang KJ and Yang YM: Tannic Acid
Promotes TRAIL-Induced extrinsic apoptosis by regulating
mitochondrial ROS in human embryonic carcinoma cells. Cells.
9:2822020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yao W, Lin Z, Shi P, Chen B, Wang G, Huang
J, Sui Y, Liu Q, Li S, Lin X, et al: Delicaflavone induces
ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk
signaling pathways in colorectal cancer cells. Biochem Pharmacol.
171:1136802020. View Article : Google Scholar : PubMed/NCBI
|
